Cited by 4,262Protein Degradation and InhibitorsChromatin Remodeling and CancerEpigenetics and DNA Methylation

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.

Selective inhibition of BET bromodomains

Open access

Filippakopoulos, Panagis, Qi, Jun, Picaud, Sarah, Shen, Yao, Smith, William B., Fedorov, Oleg, Morse, Elizabeth M., Keates, Tracey, Hickman, Tyler T., Felletar, Ildiko, Philpott, Martin, Munro, Shonagh, McKeown, Michael R., Wang, Yuchuan, Christie, Amanda L., West, Nathan, Cameron, Michael J., Schwartz, Brian, Heightman, Tom D., La Thangue, Nicholas, French, Christopher A., Wiest, Olaf, Kung, Andrew L., Knapp, Stefan, Bradner, James E.·2010·Nature

DOI 10.1038/nature09504PMC PMC3010259

Open this paper in CoChat — free account

Abstract

Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'. Potent inhibitors of histone binding modules have not yet been described. Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains. High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity. Recurrent translocation of BRD4 is observed in a genetically-defined, incurable subtype of human squamous carcinoma. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models. These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chemical scaffold for the development of chemical probes more broadly throughout the bromodomain family.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature09504

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., & Lydon, N. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2558 · Cited by 273
Retracted
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, S. R., Chai, J., Lu, J., Zhoa, L., Gu, L.-J., & Wang, Z.-Y. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability
Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,141
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Bromodomain: an acetyl‐lysine binding domain
Zeng, L., & Zhou, M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03309-9 · Cited by 751

Flagged first, then by citations

Show all 42 references

2 of the 42 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Sueoka, H., Komatsu, H., Kobayashi, H. & Ehara, S. Thienotriazolodiazepine Compounds and Medicinal Uses Thereof 1–50 (Yoshitomi Pharmaceutical Industries, Ltd, 1998)

Sorted by citations

Items 901–1,000 of 1,029

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
Wolpaw, A. J., Bayliss, R. W., Büchel, G., Dang, C. V., Eilers, M., Gustafson, W. C., Hansen, G. M., Jura, N., Knapp, S., Lemmon, M. A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3108 · Cited by 74
Self-citation
Subcellular localization of biomolecules and drug distribution by high-definition ion beam imaging
Rovira‐Clavé, X., Jiang, S., Bai, Y., Zhu, B., Barlow, G. L., Bhate, S. S., Coskun, A. F., Han, G., Ho, C. K., Hitzman, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24822-1 · Cited by 76
Targeted BRD4 protein degradation by dBET1 ameliorates acute ischemic brain injury and improves functional outcomes associated with reduced neuroinflammation and oxidative stress and preservation of blood–brain barrier integrity
Liu, L., Yang, C., Lavayen, B. P., Tishko, R. J., Larochelle, J., & Candelario‐Jalil, E. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02533-8 · Cited by 74
Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia
Zhou, J. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i4.473 · Cited by 74
Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules
Urick, A. K., Hawk, L. M. L., Cassel, M. K., Mishra, N. K., Liu, S., Adhikari, N., Zhang, W., dos Santos, C. O., Hall, J. L., & Pomerantz, W. C. K. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00483 · Cited by 74
Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer
Zhang, Z., Peng, H., Wang, X., Yin, X., Ma, P., Jing, Y., Cai, M., Liu, J., Zhang, M., Zhang, S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0078 · Cited by 74
Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathwaysPreprint
Bhattacharyya, S., Pradhan, K., Campbell, N. R., Mazdo, J., Vasantkumar, A., Maqbool, S. B., Bhagat, T. D., Gupta, S., Suzuki, M., Yu, Y., et al. (2017) · Genome Research · doi:10.1101/gr.222794.117 · Cited by 74
Self-citation
Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology
Kinnersley, B., Sud, A., Everall, A., Cornish, A. J., Chubb, D., Culliford, R., Gruber, A. J., Lärkeryd, A., Mitsopoulos, C., Wedge, D., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01785-9 · Cited by 73
Epigenetics in asthma and COPD
Kabesch, M., & Adcock, I. M. (2012) · Biochimie · doi:10.1016/j.biochi.2012.07.017 · Cited by 73
Target identification of small molecules based on chemical biology approaches
Futamura, Y., Muroi, M., & Osada, H. (2013) · Molecular BioSystems · doi:10.1039/c2mb25468a · Cited by 73
Discovery and characterization of bromodomain 2–specific inhibitors of BRDT
Yu, Z., Ku, A. F., Anglin, J. L., Sharma, R., Ucisik, M. N., Faver, J. C., Li, F., Nyshadham, P., Simmons, N., Sharma, K. L., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021102118 · Cited by 73
BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair
Ni, M., Li, J., Zhao, H., Xu, F., Cheng, J., Yu, M., Ke, G., & Wu, X. (2021) · Oncogene · doi:10.1038/s41388-021-01735-3 · Cited by 73
An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review
Sahafnejad, Z., Ramazi, S., & Allahverdi, A. (2023) · Genes · doi:10.3390/genes14040873 · Cited by 73
WHSC1 links transcription elongation to HIRA‐mediated histone H3.3 deposition
Sarai, N., Nimura, K., Tamura, T., Kanno, T., Patel, M. C., Heightman, T. D., Ura, K., & Ozato, K. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.176 · Cited by 73
Self-citation
The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
Ma, Y., Wang, L., Neitzel, L. R., Loganathan, S. N., Tang, N., Qin, L., Crispi, E. E., Guo, Y. P., Knapp, S., Beauchamp, R. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0453 · Cited by 73
Self-citation
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia
Follini, E., Marchesini, M., & Roti, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123021 · Cited by 73
Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1
Wang, L., Xu, M., Kao, C., Tsai, S. Y., & Tsai, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126327 · Cited by 73
Developing effective combination therapy for pancreatic cancer: An overview
Miller, A. L., Garcia, P. L., & Yoon, K. J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104740 · Cited by 73
BET Bromodomain Proteins as Cancer Therapeutic Targets
Shu, S., & Polyak, K. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030908 · Cited by 72
Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies
Knott, M. M. L., Hölting, T. L. B., Ohmura, S., Kirchner, T., Cidre‐Aranaz, F., & Grünewald, T. G. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09839-9 · Cited by 72
BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer
Jing, X., Shao, S. H., Zhang, Y., Luo, A., Zhao, L., Zhang, L., Gu, S., & Zhao, X. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112034 · Cited by 72
BRD4 regulates Nanog expression in mouse embryonic stem cells and preimplantation embryos
Liu, W., Stein, P., Cheng, X., Yang, W., Shao, N.-Y., Morrisey, E. E., Schultz, R. M., & You, J. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.124 · Cited by 72
Epigenetics and B-cell lymphoma
Shaknovich, R., & Melnick, A. M. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32834788cf · Cited by 74
Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity
Sartor, G. C., Powell, S. K., Brothers, S. P., & Wahlestedt, C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0826-15.2015 · Cited by 72
Characterizing the Covalent Targets of a Small Molecule Inhibitor of the Lysine Acetyltransferase P300
Shrimp, J. H., Sorum, A. W., Garlick, J. M., Guasch, L., Nicklaus, M. C., & Meier, J. L. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00385 · Cited by 72
Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma
Wu, X., Liu, D., Gao, X., Xie, F., Tao, D., Xiao, X., Wang, L., Jiang, G., & Zeng, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000472407 · Cited by 72
CIC‐NUTM1 fusion: A case which expands the spectrum of NUT ‐rearranged epithelioid malignancies
Schaefer, I., Cin, P. D., Landry, L. M., Fletcher, C. D. �., Hanna, G. J., & French, C. A. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.3 · Cited by 72
Self-citation
Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth
Ren, C., Zhang, G., Han, F., Fu, S., Cao, Y., Zhang, F., Zhang, Q., Meslamani, J. E., Xu, Y., Ji, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720000115 · Cited by 72
Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening
Wellaway, C. R., Amans, D., Bamborough, P., Barnett, H., Bit, R. A., Brown, J. A., Carlson, N. R., Chung, C., Cooper, A. W. J., Craggs, P. D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01670 · Cited by 73
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
Munshi, H., Abedin, S., & Boddy, C. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100515 · Cited by 71
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
Blake, D. R., Vaseva, A. V., Hodge, R. G., Kline, M. P., Gilbert, T. S. K., Tyagi, V., Huang, D., Whiten, G. C., Larson, J. E., Wang, X., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav7259 · Cited by 71
SPOP and cancer: a systematic review.
Clark, A. D., & Burleson, M. O. (2020) · PubMed Central · Cited by 71
Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice
Sanders, Y. Y., Lyv, X., Zhou, Q. J., Xiang, Z., Stanford, D. D., Bodduluri, S., Rowe, S. M., & Thannickal, V. J. (2020) · JCI Insight · doi:10.1172/jci.insight.137127 · Cited by 71
The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis
Drumond‐Bock, A. L., & Bieniasz, M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01424-5 · Cited by 71
Matrix metalloproteinases in rheumatoid arthritis and osteoarthritis: a state of the art review
Pulik, Ł., Łęgosz, P., & Motyl, G. (2023) · Reumatologia/Rheumatology · doi:10.5114/reum/168503 · Cited by 71
Mechanistic Analysis of the Role of Bromodomain-containing Protein 4 (BRD4) in BRD4-NUT Oncoprotein-induced Transcriptional Activation
Wang, R., & You, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.600759 · Cited by 71
Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking
Zhao, H., Gartenmann, L., Dong, J., Spiliotopoulos, D., & Caflisch, A. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.04.017 · Cited by 71
High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML
Zhao, Y., Liu, Q., Acharya, P., Stengel, K. R., Sheng, Q., Zhou, X., Kwak, H., Fischer, M. A., Bradner, J. E., Strickland, S. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.032 · Cited by 71
Self-citation
Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage
Suárez-Álvarez, B., Morgado‐Pascual, J. L., Rayego‐Mateos, S., Rodríguez, R. M. A., Rodrigues-Díez, R. R., Cannata‐Ortiz, P., Sanz, A. B., Egido, J., Tharaux, P., Ortíz, A., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015080910 · Cited by 71
Relative Binding Free Energy Calculations Applied to Protein Homology Models
Cappel, D., Hall, M. L., Lenselink, E. B., Beuming, T., Qi, J., Bradner, J. E., & Sherman, W. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00362 · Cited by 71
Self-citation
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
Peirs, S., Frismantas, V., Matthijssens, F., Loocke, W. V., Pieters, T., Vandamme, N., Lintermans, B., Dobay, M. P., Berx, G., Poppe, B. G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.10 · Cited by 71
Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma
Long, W., Yang, Y., Chen, S., Cao, Q., Zhao, W., & Liu, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00495 · Cited by 71
The role of targeted therapy in the management of patients with AML
Perl, A. E. (2017) · Hematology · doi:10.1182/asheducation-2017.1.54 · Cited by 71
Structure-Based Discovery and Optimization of Benzo[d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC)
Zhang, M., Zhang, Y., Song, M., Xue, X., Wang, J., Wang, C., Zhang, C., Li, C., Xiang, Q., Zou, L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00103 · Cited by 72
EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins
Gollavilli, P. N., Pawar, A., Wilder-Romans, K., Natesan, R., Engelke, C. G., Dommeti, V. L., Krishnamurthy, P. M., Nallasivam, A., Apel, I. J., Xu, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0484 · Cited by 71
Synthetic Lethal Screens as a Means to Understand and Treat MYC-Driven CancersPreprint
Cermelli, S., Jang, I. S., Bernard, B. M., & Grandori, C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014209 · Cited by 71
Regulation of NO Synthesis, Local Inflammation, and Innate Immunity to Pathogens by BET Family Proteins
Wienerroither, S., Rauch, I., Rosebrock, F., Jamieson, A. M., Bradner, J. E., Muhar, M., Zuber, J. A., Müller, M. M., & Decker, T. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01353-13 · Cited by 70
Self-citation
Targeting BET bromodomain proteins in cancer: The example of lymphomas
Spriano, F., Stathis, A., & Bertoni, F. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107631 · Cited by 70
Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site
Liu, Z., Li, Y., Chen, H., Lai, H., Wang, P., Wu, S., Wold, E. A., Leonard, P. G., Joseph, S., Hu, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01851 · Cited by 70
BET Bromodomain as a Target of Epigenetic Therapy
Noguchi‐Yachide, T. (2016) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c16-00225 · Cited by 70
RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC
Selvarajan, V., Osato, M., Nah, G. S. S., Yan, J., Chung, T.-H., Voon, D. C., Ito, Y., Ham, M. F., Salto‐Tellez, M., Shimizu, N., et al. (2017) · Leukemia · doi:10.1038/leu.2017.40 · Cited by 70
Attach-Pull-Release Calculations of Ligand Binding and Conformational Changes on the First BRD4 Bromodomain
Heinzelmann, G., Henriksen, N. M., & Gilson, M. K. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00275 · Cited by 72
Interrogating Histone Acetylation and BRD4 as Mitotic Bookmarks of Transcription
Behera, V., Stonestrom, A. J., Hamagami, N., Hsiung, C. C. ‐., Keller, C. A., Giardine, B. M., Sidoli, S., Yuan, Z., Bhanu, N. V., Werner, M. T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.057 · Cited by 70
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
Moreno, V., Sepúlveda-Sánchez, J. M., Vieito, M., Hernández‐Guerrero, T., Doger, B., Saavedra, O., Ferrero, O., Sarmiento, R., Arias, M., de Alvaro, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.294 · Cited by 70
Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis
Shin, J. Y., Beckett, J. D., Bagirzadeh, R., Creamer, T. J., Shah, A. A., McMahan, Z. H., Paik, J. J., Sampedro, M., MacFarlane, E. G., Beer, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw0790 · Cited by 69
Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy
Saraswat, A. L., Vemana, H. P., Dukhande, V. V., & Patel, K. R. (2022) · Heliyon · doi:10.1016/j.heliyon.2021.e08702 · Cited by 69
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment
Bartolucci, D., Montemurro, L., Raieli, S., Lampis, S., Pession, A., Hrelia, P., & Tonelli, R. (2022) · Cancers · doi:10.3390/cancers14184421 · Cited by 70
CD36-mediated endocytosis of proteolysis-targeting chimeras
Wang, Z., Pan, B., Manne, R., Chen, J., Lv, D., Wang, M., Tran, P., Weldemichael, T., Yan, W., Zhou, H., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.036 · Cited by 71
Epigenetic Control of Cytokine Gene Expression
Falvo, J. V., Jasenosky, L. D., Kruidenier, L., & Goldfeld, A. E. (2013) · Advances in immunology · doi:10.1016/b978-0-12-407708-9.00002-9 · Cited by 69
The histone code reader SPIN1 controls RET signaling in liposarcoma
Franz, H., Greschik, H., Willmann, D., Ozretić, L., Jilg, C. A., Wardelmann, E., Jung, M., Buettner, R., & Schüle, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3000 · Cited by 69
Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Loosveld, M., Castellano, R., Gon, S., Goubard, A., Crouzet, T., Pouyet, L., Prébet, T., Vey, N., Nadel, B., Collette, Y., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1873 · Cited by 69
The Chromatin Scaffold Protein SAFB1 Renders Chromatin Permissive for DNA Damage Signaling
Altmeyer, M., Toledo, L. I., Guðjόnsson, Þ., Grøfte, M., Rask, M., Lukas, C., Akimov, V., Blagoev, B., Bártek, J., & Lukas, J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.025 · Cited by 69
The basal transcription machinery as a target for cancer therapy
Villicaña, C., Cruz‐Becerra, G., & Zurita, M. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-18 · Cited by 69
A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein
Pop, M. S., Stransky, N., Garvie, C. W., Theurillat, J.-P. P., Hartman, E. C., Lewis, T. A., Zhong, C. F., Culyba, E. K., Lin, F., Daniels, D. S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0689 · Cited by 69
CXCL8 histone H3 acetylation is dysfunctional in airway smooth muscle in asthma: regulation by BET
Clifford, R. L., Patel, J. K., John, A. E., Tatler, A. L., Mazengarb, L., Brightling, C. E., & Knox, A. J. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00021.2015 · Cited by 69
Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140
Mehta, S., Cronkite, D. A., Basavappa, M. G., Saunders, T. L., Adiliaghdam, F., Amatullah, H., Morrison, S. A., Pagan, J. D., Anthony, R. M., Tonnerre, P., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aag3160 · Cited by 69
Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain
Elshan, N. G. R. D., Rettig, M. B., & Jung, M. E. (2018) · Medicinal Research Reviews · doi:10.1002/med.21548 · Cited by 69
Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells
Otto, C., Schmidt, S., Kastner, C., Denk, S., Kettler, J., Müller, N., Germer, C., Wolf, E., Gallant, P., & Wiegering, A. (2019) · Neoplasia · doi:10.1016/j.neo.2019.10.003 · Cited by 69
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors
Schafer, J. M., Lehmann, B. D., Ericsson, P. I. G., Marshall, C. B., Beeler, J. S., Redman, L. N., Jin, H., Sanchez, V. M., Stubbs, M. C., Scherle, P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8275 · Cited by 69
Native Mass Spectrometry Can Effectively Predict PROTAC Efficacy
Beveridge, R., Kessler, D., Rumpel, K., Ettmayer, P., Meinhart, A., & Clausen, T. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00049 · Cited by 71
9 H -Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain
Picaud, S., Strocchia, M., Terracciano, S., Lauro, G., Méndez, J., Daniels, D. L., Riccio, R., Bifulco, G., Bruno, I., & Filippakopoulos, P. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501893k · Cited by 68
Self-citation
The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
Hay, D. A., Fedorov, O., Filippakopoulos, P., Martin, S., Philpott, M., Picaud, S., Hewings, D. S., Uttakar, S., Heightman, T. D., Conway, S. J., et al. (2012) · MedChemComm · doi:10.1039/c2md20189e · Cited by 68
Self-citation
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors
Wadhwa, E., & Nicolaides, T. P. (2016) · Cureus · doi:10.7759/cureus.620 · Cited by 68
Chemical Specification of E3 Ubiquitin Ligase Engagement by Cysteine-Reactive Chemistry
Sarott, R. C., You, I., Li, Y.-D., Toenjes, S. T., Donovan, K. A., Seo, P., Ordonez, M., Byun, W. S., Hassan, M. M., Wachter, F., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c06622 · Cited by 70
Targeting lysine acetylation readers and writers
Zhou, M., & Cole, P. A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01080-6 · Cited by 68
Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains
Hay, D. A., Rogers, C. M., Fedorov, O., Tallant, C., Martin, S., Monteiro, O., Müller, S., Knapp, S., Schofield, C. J., & Brennan, P. E. (2015) · MedChemComm · doi:10.1039/c5md00152h · Cited by 68
Self-citation
Brd4 bridges the transcriptional regulators, Aire and P-TEFb, to promote elongation of peripheral-tissue antigen transcripts in thymic stromal cells
Yoshida, H., Bansal, K., Schaefer, U., Chapman, T. D., Rioja, I., Proekt, I., Anderson, M. S., Prinjha, R. K., Tarakhovsky, A., Benoist, C. O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512081112 · Cited by 68
Combinatorial Readout of Dual Histone Modifications by Paired Chromatin-associated Modules
Wang, Z., & Patel, D. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.219139 · Cited by 68
Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives
Andreoli, F., Barbosa, A. J. M., Parenti, M. D., & Río, A. D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804581918 · Cited by 68
Epigenetic regulation of cardiac fibrosis
Stratton, M. S., & McKinsey, T. A. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.02.011 · Cited by 68
The control of male fertility by spermatid-specific factors: searching for contraceptive targets from spermatozoon’s head to tail
Chen, S., Batool, A., Wang, Y., Hao, X., Chang, C., Cheng, C. Y., & Liu, Y. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.344 · Cited by 68
Self-citation
Targeting Chromatin Remodeling for Cancer Therapy
Kaur, J., Daoud, A., & Eblen, S. T. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666190215112915 · Cited by 69
Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment
Hu, Z., Zhou, J., Jiang, J., Yuan, J., Zhang, Y., Wei, X., Loo, N., Wang, Y., Pan, Y., Zhang, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08554-x · Cited by 68
Self-citation
Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma
Wu, Y., Wang, Y., Diao, P., Zhang, W., Li, J., Ge, H., Song, Y., Li, Z., Wang, D., Liu, L., et al. (2019) · Theranostics · doi:10.7150/thno.31581 · Cited by 68
Self-citation
The role of targeted therapy in the management of patients with AML
Perl, A. E. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009829 · Cited by 68
Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2
Liu, S., Walker, S. R., Nelson, E. A., Cerulli, R. A., Xiang, M. H., Toniolo, P. A., Qi, J., Stone, R. M., Wadleigh, M., Bradner, J. E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0341 · Cited by 67
Self-citation
Competitive Binding of a Benzimidazole to the Histone-Binding Pocket of the Pygo PHD Finger
Miller, T. C. R., Rutherford, T. J., Birchall, K., Chugh, J., Fiedler, M., & Bienz, M. (2014) · ACS Chemical Biology · doi:10.1021/cb500585s · Cited by 67
The Fra-1/AP-1 Oncoprotein: From the “Undruggable” Transcription Factor to Therapeutic Targeting
Casalino, L., Talotta, F., Cimmino, A., & Verde, P. (2022) · Cancers · doi:10.3390/cancers14061480 · Cited by 67
The effects of MYC on tumor immunity and immunotherapy
Li, J., Dong, T., Wu, Z., Zhu, D., & Gu, H. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01403-3 · Cited by 67
Histone Recognition by Human Malignant Brain Tumor Domains
Nady, N., Krichevsky, L., Zhong, N., Duan, S., Tempel, W., Amaya, M. F., Ravichandran, M., & Arrowsmith, C. H. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.08.022 · Cited by 67
Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma
Hensel, T., Giorgi, C., Schmidt, O., Calzada‐Wack, J., Neff, F., Buch, T., Niggli, F. K., Schäfer, B. W., Burdach, S. E. G., & Richter, G. H. S. (2015) · Oncotarget · doi:10.18632/oncotarget.6385 · Cited by 67
GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain
Bamborough, P., Barnett, H., Becher, I., Bird, M. J., Chung, C., Craggs, P. D., Demont, E. H., Diallo, H., Fallon, D. J., Gordon, L. J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00092 · Cited by 67
Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles
Jiang, X., Bugno, J., Hu, C., Yang, Y., Herold, T., Qi, J., Chen, P., Gurbuxani, S. K., Arnovitz, S., Strong, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2949 · Cited by 67
Self-citation
The suppression of bromodomain and extra‐terminal domain inhibits vascular inflammation by blocking NF‐κB and MAPK activation
Huang, M., Zeng, S., Zou, Y., Shi, M., Qiu, Q., Xiao, Y., Chen, G., Yang, X., Liang, L., & Xu, H. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13657 · Cited by 67
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors
Wang, L., Pratt, J. K., Soltwedel, T., Sheppard, G. S., Fidanze, S. D., Liu, D., Hasvold, L. A., Mantei, R. A., Holms, J. H., McClellan, W. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00017 · Cited by 67
Self-citation
Lymphoma classification update: B-cell non-Hodgkin lymphomas
Jiang, M., Bennani, N. N., & Feldman, A. L. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1318053 · Cited by 67
Developing Spindlin1 small-molecule inhibitors by using protein microarrays
Bae, N., Viviano, M., Su, X., Lv, J., Cheng, D., Sagum, C. A., Castellano, S., Bai, X., Johnson, C., Khalil, M. I. M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2377 · Cited by 67
The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators
Wai, D. C. C., Szyszka, T. N., Campbell, A. E., Kwong, C., Wilkinson‐White, L. E., Silva, A. P. G., Low, J. K. K., Kwan, A. H., Gamsjaeger, R., Chalmers, J. D., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000678 · Cited by 67
“Z4” Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism
Shiota, H., Elya, J. E., Alekseyenko, A. A., Chou, P. M., Gorman, S., Barbash, O., Becht, K., Danga, K., Kuroda, M. I., Nardi, V., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0474 · Cited by 67
Self-citation
Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives
Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65

Authors: Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., & Bradner, J. E.
Affiliations: University of Oxford (GB)
Harvard University (US)
University of Notre Dame (US)
Brigham and Women's Hospital (US)
Boston Children's Hospital (US)
Corresponding author: Knapp, Stefan
Bradner, James E.
ORCID: Filippakopoulos, Panagis
Qi, Jun
Picaud, Sarah
Shen, Yao
Fedorov, Oleg
Hickman, Tyler T.
Philpott, Martin
Munro, Shonagh
McKeown, Michael R.
Wang, Yuchuan
Schwartz, Brian
Heightman, Tom D.
French, Christopher A.
Wiest, Olaf
Kung, Andrew L.
Knapp, Stefan
Bradner, James E.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2010-09-24
Volume: 468
Issue: 7327
Pages: 1067-1073
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature09504
PMC: PMC3010259
OpenAlex: W2041535798
Cited by: 4,262
References: 42
Citations by year: 2026: 217 · 2025: 307 · 2024: 304 · 2023: 307 · 2022: 309 · 2021: 323 · 2020: 340 · 2019: 323 · 2018: 303 · 2017: 306 · 2016: 334 · 2015: 279 · 2014: 246 · 2013: 177 · 2012: 117
FWCI: 48.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
Funders: Wellcome Trust
Cancer Research UK (13058)
U.S. Public Health Service (T32-075762)
Canadian Institutes of Health Research
National Cancer Institute (K08CA128972)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords: BET inhibitors, JQ1, BRD4, epigenetic reader protein, protein-protein interaction inhibition, squamous cell carcinoma, histone acetylation, co-crystal structure, chemical probes, transcriptional regulation
MeSH terms: Bromodomain Containing Proteins, Amino Acid Sequence, Animals, Azirines, Binding Sites, Carcinoma, Squamous Cell, Cell Differentiation, Chromatin, Dihydropyridines, Female, Humans, Mice, Nude, Models, Molecular, Molecular Sequence Data, Nuclear Proteins, Protein Binding, Recombinant Proteins, Skin Neoplasms, Stereoisomerism, Transcription Factors, Sequence Alignment, Protein Structure, Tertiary, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Selective inhibition of BET bromodomains

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks